ICH
ICH Q7
Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients
Current Step 4 version
Table of contents
- 1INTRODUCTION
- 1.1Objective
- 1.2Regulatory Applicability
- 1.3Scope
- 2QUALITY MANAGEMENT
- 2.1Principles
- 2.10Quality should be the responsibility of all persons involved in manufacturing.
- 2.11Each manufacturer should establish, document, and implement an effective system for managing quality that involves the active participation…
- 2.12The system for managing quality should encompass the organisational structure, procedures, processes and resources, as well as activities n…
- 2.13There should be a quality unit(s) that is independent of production and that fulfills both quality assurance (QA) and quality control (QC)…
- 2.14The persons authorised to release intermediates and APIs should be specified.
- 2.15All quality related activities should be recorded at the time they are performed.
- 2.16Any deviation from established procedures should be documented and explained. Critical deviations should be investigated, and the investiga…
- 2.17No materials should be released or used before the satisfactory completion of evaluation by the quality unit(s) unless there are appropriat…
- 2.18Procedures should exist for notifying responsible management in a timely manner of regulatory inspections, serious GMP deficiencies, produc…
- 2.2Responsibilities of the Quality Unit(s)
- 2.20The quality unit(s) should be involved in all quality-related matters.
- 2.21The quality unit(s) should review and approve all appropriate quality-related documents.
- 2.22The main responsibilities of the independent quality unit(s) should not be delegated. These responsibilities should be described in writing…
- 2.3Responsibility for Production Activities
- 2.4Internal Audits (Self Inspection)
- 2.40In order to verify compliance with the principles of GMP for APIs, regular internal audits should be performed in accordance with an approv…
- 2.41Audit findings and corrective actions should be documented and brought to the attention of responsible management of the firm. Agreed corre…
- 2.5Product Quality Review
- 2.50Regular quality reviews of APIs should be conducted with the objective of verifying the consistency of the process. Such reviews should nor…
- 2.51The results of this review should be evaluated and an assessment made of whether corrective action or any revalidation should be undertaken…
- 3PERSONNEL
- 3.1Personnel Qualifications
- 3.10There should be an adequate number of personnel qualified by appropriate education, training and/or experience to perform and supervise the…
- 3.11The responsibilities of all personnel engaged in the manufacture of intermediates and APIs should be specified in writing.
- 3.12Training should be regularly conducted by qualified individuals and should cover, at a minimum, the particular operations that the employee…
- 3.2Personnel Hygiene
- 3.20Personnel should practice good sanitation and health habits.
- 3.21Personnel should wear clean clothing suitable for the manufacturing activity with which they are involved and this clothing should be chang…
- 3.22Personnel should avoid direct contact with intermediates or APIs.
- 3.23Smoking, eating, drinking, chewing and the storage of food should be restricted to certain designated areas separate from the manufacturing…
- 3.24Personnel suffering from an infectious disease or having open lesions on the exposed surface of the body should not engage in activities th…
- 3.3Consultants
- 3.30Consultants advising on the manufacture and control of intermediates or APIs should have sufficient education, training, and experience, or…
- 3.31Records should be maintained stating the name, address, qualifications, and type of service provided by these consultants.
- 4BUILDINGS AND FACILITIES
- 4.1Design and Construction
- 4.10Buildings and facilities used in the manufacture of intermediates and APIs should be located, designed, and constructed to facilitate clean…
- 4.11Buildings and facilities should have adequate space for the orderly placement of equipment and materials to prevent mix-ups and contaminati…
- 4.12Where the equipment itself (e.g., closed or contained systems) provides adequate protection of the material, such equipment can be located…
- 4.13The flow of materials and personnel through the building or facilities should be designed to prevent mix-ups or contamination.
- 4.14There should be defined areas or other control systems for the following activities: - Receipt, identification, sampling, and quarantine of…
- 4.15Adequate, clean washing and toilet facilities should be provided for personnel. These washing facilities should be equipped with hot and co…
- 4.16Laboratory areas/operations should normally be separated from production areas. Some laboratory areas, in particular those used for in-proc…
- 4.2Utilities
- 4.20All utilities that could impact on product quality (e.g. steam, gases, compressed air, and heating, ventilation and air conditioning) shoul…
- 4.21Adequate ventilation, air filtration and exhaust systems should be provided, where appropriate. These systems should be designed and constr…
- 4.22If air is recirculated to production areas, appropriate measures should be taken to control risks of contamination and cross-contamination.
- 4.23Permanently installed pipework should be appropriately identified. This can be accomplished by identifying individual lines, documentation,…
- 4.24Drains should be of adequate size and should be provided with an air break or a suitable device to prevent back-siphonage, when appropriate.
- 4.3Water
- 4.30Water used in the manufacture of APIs should be demonstrated to be suitable for its intended use.
- 4.31Unless otherwise justified, process water should, at a minimum, meet World Health Organization (WHO) guidelines for drinking (potable) wate…
- 4.32If drinking (potable) water is insufficient to assure API quality, and tighter chemical and/or microbiological water quality specifications…
- 4.33Where water used in the process is treated by the manufacturer to achieve a defined quality, the treatment process should be validated and…
- 4.34Where the manufacturer of a non-sterile API either intends or claims that it is suitable for use in further processing to produce a sterile…
- 4.4Containment
- 4.40Dedicated production areas, which can include facilities, air handling equipment and/or process equipment, should be employed in the produc…
- 4.41Dedicated production areas should also be considered when material of an infectious nature or high pharmacological activity or toxicity is…
- 4.42Appropriate measures should be established and implemented to prevent cross-contamination from personnel, materials, etc. moving from one d…
- 4.43Any production activities (including weighing, milling, or packaging) of highly toxic non-pharmaceutical materials such as herbicides and p…
- 4.5Lighting
- 4.50Adequate lighting should be provided in all areas to facilitate cleaning, maintenance, and proper operations.
- 4.6Sewage and Refuse
- 4.60Sewage, refuse, and other waste (e.g., solids, liquids, or gaseous by-products from manufacturing) in and from buildings and the immediate…
- 4.7Sanitation and Maintenance
- 4.70Buildings used in the manufacture of intermediates and APIs should be properly maintained and repaired and kept in a clean condition.
- 4.71Written procedures should be established assigning responsibility for sanitation and describing the cleaning schedules, methods, equipment,…
- 4.72When necessary, written procedures should also be established for the use of suitable rodenticides, insecticides, fungicides, fumigating ag…
- 5PROCESS EQUIPMENT
- 5.1Design and Construction
- 5.10Equipment used in the manufacture of intermediates and APIs should be of appropriate design and adequate size, and suitably located for its…
- 5.11Equipment should be constructed so that surfaces that contact raw materials, intermediates, or APIs do not alter the quality of the interme…
- 5.12Production equipment should only be used within its qualified operating range.
- 5.13Major equipment (e.g., reactors, storage containers) and permanently installed processing lines used during the production of an intermedia…
- 5.14Any substances associated with the operation of equipment, such as lubricants, heating fluids or coolants, should not contact intermediates…
- 5.15Closed or contained equipment should be used whenever appropriate. Where open equipment is used, or equipment is opened, appropriate precau…
- 5.16A set of current drawings should be maintained for equipment and critical installations (e.g., instrumentation and utility systems).
- 5.2Equipment Maintenance and Cleaning
- 5.20Schedules and procedures (including assignment of responsibility) should be established for the preventative maintenance of equipment.
- 5.21Written procedures should be established for cleaning of equipment and its subsequent release for use in the manufacture of intermediates a…
- 5.22Equipment and utensils should be cleaned, stored, and, where appropriate, sanitized or sterilized to prevent contamination or carry-over of…
- 5.23Where equipment is assigned to continuous production or campaign production of successive batches of the same intermediate or API, equipmen…
- 5.24Non-dedicated equipment should be cleaned between production of different materials to prevent cross-contamination.
- 5.25Acceptance criteria for residues and the choice of cleaning procedures and cleaning agents should be defined and justified.
- 5.26Equipment should be identified as to its contents and its cleanliness status by appropriate means.
- 5.3Calibration
- 5.30Control, weighing, measuring, monitoring and test equipment that is critical for assuring the quality of intermediates or APIs should be ca…
- 5.31Equipment calibrations should be performed using standards traceable to certified standards, if existing.
- 5.32Records of these calibrations should be maintained.
- 5.33The current calibration status of critical equipment should be known and verifiable.
- 5.34Instruments that do not meet calibration criteria should not be used.
- 5.35Deviations from approved standards of calibration on critical instruments should be investigated to determine if these could have had an im…
- 5.4Computerized Systems
- 5.40GMP related computerized systems should be validated. The depth and scope of validation depends on the diversity, complexity and criticalit…
- 5.41Appropriate installation qualification and operational qualification should demonstrate the suitability of computer hardware and software t…
- 5.42Commercially available software that has been qualified does not require the same level of testing. If an existing system was not validated…
- 5.43Computerized systems should have sufficient controls to prevent unauthorized access or changes to data. There should be controls to prevent…
- 5.44Written procedures should be available for the operation and maintenance of computerized systems.
- 5.45Where critical data are being entered manually, there should be an additional check on the accuracy of the entry. This can be done by a sec…
- 5.46Incidents related to computerized systems that could affect the quality of intermediates or APIs or the reliability of records or test resu…
- 5.47Changes to the computerized system should be made according to a change procedure and should be formally authorized, documented and tested.…
- 5.48If system breakdowns or failures would result in the permanent loss of records, a back-up system should be provided. A means of ensuring da…
- 5.49Data can be recorded by a second means in addition to the computer system.
- 6DOCUMENTATION AND RECORDS
- 6.1Documentation System and Specifications
- 6.10All documents related to the manufacture of intermediates or APIs should be prepared, reviewed, approved and distributed according to writt…
- 6.11The issuance, revision, superseding and withdrawal of all documents should be controlled with maintenance of revision histories.
- 6.12A procedure should be established for retaining all appropriate documents (e.g., development history reports, scale-up reports, technical t…
- 6.13All production, control, and distribution records should be retained for at least 1 year after the expiry date of the batch. For APIs with…
- 6.14When entries are made in records, these should be made indelibly in spaces provided for such entries, directly after performing the activit…
- 6.15During the retention period, originals or copies of records should be readily available at the establishment where the activities described…
- 6.16Specifications, instructions, procedures, and records can be retained either as originals or as true copies such as photocopies, microfilm,…
- 6.17Specifications should be established and documented for raw materials, intermediates where necessary, APIs, and labelling and packaging mat…
- 6.18If electronic signatures are used on documents, they should be authenticated and secure.
- 6.2Equipment Cleaning and Use Record
- 6.20Records of major equipment use, cleaning, sanitization and/or sterilization and maintenance should show the date, time (if appropriate), pr…
- 6.21If equipment is dedicated to manufacturing one intermediate or API, then individual equipment records are not necessary if batches of the i…
- 6.3Records of Raw Materials, Intermediates, API Labelling and Packaging Materials
- 6.30Records should be maintained including: - The name of the manufacturer, identity and quantity of each shipment of each batch of raw materia…
- 6.31Master (approved) labels should be maintained for comparison to issued labels.
- 6.4Master Production Instructions (Master Production and Control Records)
- 6.40To ensure uniformity from batch to batch, master production instructions for each intermediate and API should be prepared, dated, and signe…
- 6.41Master production instructions should include: - The name of the intermediate or API being manufactured and an identifying document referen…
- 6.5Batch Production Records (Batch Production and Control Records)
- 6.50Batch production records should be prepared for each intermediate and API and should include complete information relating to the productio…
- 6.51These records should be numbered with a unique batch or identification number, dated and signed when issued. In continuous production, the…
- 6.52Documentation of completion of each significant step in the batch production records (batch production and control records) should include:…
- 6.53Written procedures should be established and followed for investigating critical deviations or the failure of a batch of intermediate or AP…
- 6.6Laboratory Control Records
- 6.60Laboratory control records should include complete data derived from all tests conducted to ensure compliance with established specificatio…
- 6.61Complete records should also be maintained for: - Any modifications to an established analytical method; - Periodic calibration of laborato…
- 6.7Batch Production Record Review
- 6.70Written procedures should be established and followed for the review and approval of batch production and laboratory control records, inclu…
- 6.71Batch production and laboratory control records of critical process steps should be reviewed and approved by the quality unit(s) before an…
- 6.72All deviation, investigation, and OOS reports should be reviewed as part of the batch record review before the batch is released.
- 6.73The quality unit(s) can delegate to the production unit the responsibility and authority for release of intermediates, except for those shi…
- 7MATERIALS MANAGEMENT
- 7.1General Controls
- 7.10There should be written procedures describing the receipt, identification, quarantine, storage, handling, sampling, testing, and approval o…
- 7.11Manufacturers of intermediates and/or APIs should have a system for evaluating the suppliers of critical materials.
- 7.12Materials should be purchased against an agreed specification, from a supplier or suppliers approved by the quality unit(s).
- 7.13If the supplier of a critical material is not the manufacturer of that material, the name and address of that manufacturer should be known…
- 7.14Changing the source of supply of critical raw materials should be treated according to Section 13, Change Control.
- 7.2Receipt and Quarantine
- 7.20Upon receipt and before acceptance, each container or grouping of containers of materials should be examined visually for correct labelling…
- 7.21Before incoming materials are mixed with existing stocks (e.g., solvents or stocks in silos), they should be identified as correct, tested,…
- 7.22If bulk deliveries are made in non-dedicated tankers, there should be assurance of no cross-contamination from the tanker. Means of providi…
- 7.23Large storage containers, and their attendant manifolds, filling and discharge lines should be appropriately identified.
- 7.24Each container or grouping of containers (batches) of materials should be assigned and identified with a distinctive code, batch, or receip…
- 7.3Sampling and Testing of Incoming Production Materials
- 7.30At least one test to verify the identity of each batch of material should be conducted, with the exception of the materials described below…
- 7.31Supplier approval should include an evaluation that provides adequate evidence (e.g., past quality history) that the manufacturer can consi…
- 7.32Processing aids, hazardous or highly toxic raw materials, other special materials, or materials transferred to another unit within the comp…
- 7.33Samples should be representative of the batch of material from which they are taken. Sampling methods should specify the number of containe…
- 7.34Sampling should be conducted at defined locations and by procedures designed to prevent contamination of the material sampled and contamina…
- 7.35Containers from which samples are withdrawn should be opened carefully and subsequently reclosed. They should be marked to indicate that a…
- 7.4Storage
- 7.40Materials should be handled and stored in a manner to prevent degradation, contamination, and cross-contamination.
- 7.41Materials stored in fiber drums, bags, or boxes should be stored off the floor and, when appropriate, suitably spaced to permit cleaning an…
- 7.42Materials should be stored under conditions and for a period that have no adverse affect on their quality, and should normally be controlle…
- 7.43Certain materials in suitable containers can be stored outdoors, provided identifying labels remain legible and containers are appropriatel…
- 7.44Rejected materials should be identified and controlled under a quarantine system designed to prevent their unauthorised use in manufacturin…
- 7.5Re-evaluation
- 7.50Materials should be re-evaluated as appropriate to determine their suitability for use (e.g., after prolonged storage or exposure to heat o…
- 8PRODUCTION AND IN-PROCESS CONTROLS
- 8.1Production Operations
- 8.10Raw materials for intermediate and API manufacturing should be weighed or measured under appropriate conditions that do not affect their su…
- 8.11If a material is subdivided for later use in production operations, the container receiving the material should be suitable and should be s…
- 8.12Critical weighing, measuring, or subdividing operations should be witnessed or subjected to an equivalent control. Prior to use, production…
- 8.13Other critical activities should be witnessed or subjected to an equivalent control.
- 8.14Actual yields should be compared with expected yields at designated steps in the production process. Expected yields with appropriate range…
- 8.15Any deviation should be documented and explained. Any critical deviation should be investigated.
- 8.16The processing status of major units of equipment should be indicated either on the individual units of equipment or by appropriate documen…
- 8.17Materials to be reprocessed or reworked should be appropriately controlled to prevent unauthorized use.
- 8.2Time Limits
- 8.20If time limits are specified in the master production instruction (see 6.41), these time limits should be met to ensure the quality of inte…
- 8.21Intermediates held for further processing should be stored under appropriate conditions to ensure their suitability for use.
- 8.3In-process Sampling and Controls
- 8.30Written procedures should be established to monitor the progress and control the performance of processing steps that cause variability in…
- 8.31The acceptance criteria and type and extent of testing can depend on the nature of the intermediate or API being manufactured, the reaction…
- 8.32Critical in-process controls (and critical process monitoring), including the control points and methods, should be stated in writing and a…
- 8.33In-process controls can be performed by qualified production department personnel and the process adjusted without prior quality unit(s) ap…
- 8.34Written procedures should describe the sampling methods for in-process materials, intermediates, and APIs. Sampling plans and procedures sh…
- 8.35In-process sampling should be conducted using procedures designed to prevent contamination of the sampled material and other intermediates…
- 8.36Out-of-specification (OOS) investigations are not normally needed for in-process tests that are performed for the purpose of monitoring and…
- 8.4Blending Batches of Intermediates or APIs
- 8.40For the purpose of this document, blending is defined as the process of combining materials within the same specification to produce a homo…
- 8.41Out-Of-Specification batches should not be blended with other batches for the purpose of meeting specifications. Each batch incorporated in…
- 8.42Acceptable blending operations include but are not limited to: - Blending of small batches to increase batch size - Blending of tailings (i…
- 8.43Blending processes should be adequately controlled and documented and the blended batch should be tested for conformance to established spe…
- 8.44The batch record of the blending process should allow traceability back to the individual batches that make up the blend.
- 8.45Where physical attributes of the API are critical (e.g., APIs intended for use in solid oral dosage forms or suspensions), blending operati…
- 8.46If the blending could adversely affect stability, stability testing of the final blended batches should be performed.
- 8.47The expiry or retest date of the blended batch should be based on the manufacturing date of the oldest tailings or batch in the blend.
- 8.5Contamination Control
- 8.50Residual materials can be carried over into successive batches of the same intermediate or API if there is adequate control. Examples inclu…
- 8.51Production operations should be conducted in a manner that will prevent contamination of intermediates or APIs by other materials.
- 8.52Precautions to avoid contamination should be taken when APIs are handled after purification. 9. PACKAGING AND IDENTIFICATION LABELLING OF A…
- 9.1General
- 9.10There should be written procedures describing the receipt, identification, quarantine, sampling, examination and/or testing and release, an…
- 9.11Packaging and labelling materials should conform to established specifications. Those that do not comply with such specifications should be…
- 9.12Records should be maintained for each shipment of labels and packaging materials showing receipt, examination, or testing, and whether acce…
- 9.2Packaging Materials
- 9.20Containers should provide adequate protection against deterioration or contamination of the intermediate or API that may occur during trans…
- 9.21Containers should be clean and, where indicated by the nature of the intermediate or API, sanitized to ensure that they are suitable for th…
- 9.22If containers are re-used, they should be cleaned in accordance with documented procedures and all previous labels should be removed or def…
- 9.3Label Issuance and Control
- 9.30Access to the label storage areas should be limited to authorised personnel.
- 9.31Procedures should be used to reconcile the quantities of labels issued, used, and returned and to evaluate discrepancies found between the…
- 9.32All excess labels bearing batch numbers or other batch-related printing should be destroyed. Returned labels should be maintained and store…
- 9.33Obsolete and out-dated labels should be destroyed.
- 9.34Printing devices used to print labels for packaging operations should be controlled to ensure that all imprinting conforms to the print spe…
- 9.35Printed labels issued for a batch should be carefully examined for proper identity and conformity to specifications in the master productio…
- 9.36A printed label representative of those used should be included in the batch production record.
- 9.4Packaging and Labelling Operations
- 9.40There should be documented procedures designed to ensure that correct packaging materials and labels are used.
- 9.41Labelling operations should be designed to prevent mix-ups. There should be physical or spatial separation from operations involving other…
- 9.42Labels used on containers of intermediates or APIs should indicate the name or identifying code, the batch number of the product, and stora…
- 9.43If the intermediate or API is intended to be transferred outside the control of the manufacturer’s material management system, the name and…
- 9.44Packaging and labelling facilities should be inspected immediately before use to ensure that all materials not needed for the next packagin…
- 9.45Packaged and labelled intermediates or APIs should be examined to ensure that containers and packages in the batch have the correct label.…
- 9.46Intermediate or API containers that are transported outside of the manufacturer's control should be sealed in a manner such that, if the se…
- 10STORAGE AND DISTRIBUTION
- 10.1Warehousing Procedures
- 10.10Facilities should be available for the storage of all materials under appropriate conditions (e.g. controlled temperature and humidity when…
- 10.11Unless there is an alternative system to prevent the unintentional or unauthorised use of quarantined, rejected, returned, or recalled mate…
- 10.2Distribution Procedures
- 10.20APIs and intermediates should only be released for distribution to third parties after they have been released by the quality unit(s). APIs…
- 10.21APIs and intermediates should be transported in a manner that does not adversely affect their quality.
- 10.22Special transport or storage conditions for an API or intermediate should be stated on the label.
- 10.23The manufacturer should ensure that the contract acceptor (contractor) for transportation of the API or intermediate knows and follows the…
- 10.24A system should be in place by which the distribution of each batch of intermediate and/or API can be readily determined to permit its reca…
- 11LABORATORY CONTROLS
- 11.1General Controls
- 11.10The independent quality unit(s) should have at its disposal adequate laboratory facilities.
- 11.11There should be documented procedures describing sampling, testing, approval or rejection of materials, and recording and storage of labora…
- 11.12All specifications, sampling plans, and test procedures should be scientifically sound and appropriate to ensure that raw materials, interm…
- 11.13Appropriate specifications should be established for APIs in accordance with accepted standards and consistent with the manufacturing proce…
- 11.14Laboratory controls should be followed and documented at the time of performance. Any departures from the above described procedures should…
- 11.15Any out-of-specification result obtained should be investigated and documented according to a procedure. This procedure should require anal…
- 11.16Reagents and standard solutions should be prepared and labelled following written procedures. “Use by” dates should be applied as appropria…
- 11.17Primary reference standards should be obtained as appropriate for the manufacture of APIs. The source of each primary reference standard sh…
- 11.18Where a primary reference standard is not available from an officially recognized source, an “in-house primary standard” should be establis…
- 11.19Secondary reference standards should be appropriately prepared, identified, tested, approved, and stored. The suitability of each batch of…
- 11.2Testing of Intermediates and APIs
- 11.20For each batch of intermediate and API, appropriate laboratory tests should be conducted to determine conformance to specifications.
- 11.21An impurity profile describing the identified and unidentified impurities present in a typical batch produced by a specific controlled prod…
- 11.22The impurity profile should be compared at appropriate intervals against the impurity profile in the regulatory submission or compared agai…
- 11.23Appropriate microbiological tests should be conducted on each batch of intermediate and API where microbial quality is specified.
- 11.3Validation of Analytical Procedures - see Section 12.
- 11.4Certificates of Analysis
- 11.40Authentic Certificates of Analysis should be issued for each batch of intermediate or API on request.
- 11.41Information on the name of the intermediate or API including where appropriate its grade, the batch number, and the date of release should…
- 11.42The Certificate should list each test performed in accordance with compendial or customer requirements, including the acceptance limits, an…
- 11.43Certificates should be dated and signed by authorised personnel of the quality unit(s) and should show the name, address and telephone numb…
- 11.44If new Certificates are issued by or on behalf of repackers/reprocessors, agents or brokers, these Certificates should show the name, addre…
- 11.5Stability Monitoring of APIs
- 11.50A documented, on-going testing program should be designed to monitor the stability characteristics of APIs, and the results should be used…
- 11.51The test procedures used in stability testing should be validated and be stability indicating.
- 11.52Stability samples should be stored in containers that simulate the market container. For example, if the API is marketed in bags within fib…
- 11.53Normally the first three commercial production batches should be placed on the stability monitoring program to confirm the retest or expiry…
- 11.54Thereafter, at least one batch per year of API manufactured (unless none is produced that year) should be added to the stability monitoring…
- 11.55For APIs with short shelf-lives, testing should be done more frequently. For example, for those biotechnological/biologic and other APIs wi…
- 11.56Where appropriate, the stability storage conditions should be consistent with the ICH guidelines on stability.
- 11.6Expiry and Retest Dating
- 11.60When an intermediate is intended to be transferred outside the control of the manufacturer’s material management system and an expiry or re…
- 11.61An API expiry or retest date should be based on an evaluation of data derived from stability studies. Common practice is to use a retest da…
- 11.62Preliminary API expiry or retest dates can be based on pilot scale batches if (1) the pilot batches employ a method of manufacture and proc…
- 11.63A representative sample should be taken for the purpose of performing a retest.
- 11.7Reserve/Retention Samples
- 11.70The packaging and holding of reserve samples is for the purpose of potential future evaluation of the quality of batches of API and not for…
- 11.71Appropriately identified reserve samples of each API batch should be retained for one year after the expiry date of the batch assigned by t…
- 11.72The reserve sample should be stored in the same packaging system in which the API is stored or in one that is equivalent to or more protect…
- 12VALIDATION
- 12.1Validation Policy
- 12.10The company's overall policy, intentions, and approach to validation, including the validation of production processes, cleaning procedures…
- 12.11The critical parameters/attributes should normally be identified during the development stage or from historical data, and the ranges neces…
- 12.12Validation should extend to those operations determined to be critical to the quality and purity of the API.
- 12.2Validation Documentation
- 12.20A written validation protocol should be established that specifies how validation of a particular process will be conducted. The protocol s…
- 12.21The validation protocol should specify critical process steps and acceptance criteria as well as the type of validation to be conducted (e.…
- 12.22A validation report that cross-references the validation protocol should be prepared, summarising the results obtained, commenting on any d…
- 12.23Any variations from the validation protocol should be documented with appropriate justification.
- 12.3Qualification
- 12.30Before starting process validation activities, appropriate qualification of critical equipment and ancillary systems should be completed. Q…
- 12.4Approaches to Process Validation
- 12.40Process Validation (PV) is the documented evidence that the process, operated within established parameters, can perform effectively and re…
- 12.41There are three approaches to validation. Prospective validation is the preferred approach, but there are exceptions where the other approa…
- 12.42Prospective validation should normally be performed for all API processes as defined in 12.12. Prospective validation performed on an API p…
- 12.43Concurrent validation can be conducted when data from replicate production runs are unavailable because only a limited number of API batche…
- 12.44An exception can be made for retrospective validation for well established processes that have been used without significant changes to API…
- 12.45Batches selected for retrospective validation should be representative of all batches made during the review period, including any batches…
- 12.5Process Validation Program
- 12.50The number of process runs for validation should depend on the complexity of the process or the magnitude of the process change being consi…
- 12.51Critical process parameters should be controlled and monitored during process validation studies. Process parameters unrelated to quality,…
- 12.52Process validation should confirm that the impurity profile for each API is within the limits specified. The impurity profile should be com…
- 12.6Periodic Review of Validated Systems
- 12.60Systems and processes should be periodically evaluated to verify that they are still operating in a valid manner. Where no significant chan…
- 12.7Cleaning Validation
- 12.70Cleaning procedures should normally be validated. In general, cleaning validation should be directed to situations or process steps where c…
- 12.71Validation of cleaning procedures should reflect actual equipment usage patterns. If various APIs or intermediates are manufactured in the…
- 12.72The cleaning validation protocol should describe the equipment to be cleaned, procedures, materials, acceptable cleaning levels, parameters…
- 12.73Sampling should include swabbing, rinsing, or alternative methods (e.g., direct extraction), as appropriate, to detect both insoluble and s…
- 12.74Validated analytical methods having sensitivity to detect residues or contaminants should be used. The detection limit for each analytical…
- 12.75Equipment cleaning/sanitization studies should address microbiological and endotoxin contamination for those processes where there is a nee…
- 12.76Cleaning procedures should be monitored at appropriate intervals after validation to ensure that these procedures are effective when used d…
- 12.8Validation of Analytical Methods
- 12.80Analytical methods should be validated unless the method employed is included in the relevant pharmacopoeia or other recognised standard re…
- 12.81Methods should be validated to include consideration of characteristics included within the ICH guidelines on validation of analytical meth…
- 12.82Appropriate qualification of analytical equipment should be considered before starting validation of analytical methods.
- 12.83Complete records should be maintained of any modification of a validated analytical method. Such records should include the reason for the…
- 13CHANGE CONTROL
- 13.10A formal change control system should be established to evaluate all changes that may affect the production and control of the intermediate…
- 13.11Written procedures should provide for the identification, documentation, appropriate review, and approval of changes in raw materials, spec…
- 13.12Any proposals for GMP relevant changes should be drafted, reviewed, and approved by the appropriate organisational units, and reviewed and…
- 13.13The potential impact of the proposed change on the quality of the intermediate or API should be evaluated. A classification procedure may h…
- 13.14When implementing approved changes, measures should be taken to ensure that all documents affected by the changes are revised.
- 13.15After the change has been implemented, there should be an evaluation of the first batches produced or tested under the change.
- 13.16The potential for critical changes to affect established retest or expiry dates should be evaluated. If necessary, samples of the intermedi…
- 13.17Current dosage form manufacturers should be notified of changes from established production and process control procedures that can impact…
- 14REJECTION AND RE-USE OF MATERIALS
- 14.1Rejection
- 14.10Intermediates and APIs failing to meet established specifications should be identified as such and quarantined. These intermediates or APIs…
- 14.2Reprocessing
- 14.20Introducing an intermediate or API, including one that does not conform to standards or specifications, back into the process and reprocess…
- 14.21Continuation of a process step after an in-process control test has shown that the step is incomplete is considered to be part of the norma…
- 14.22Introducing unreacted material back into a process and repeating a chemical reaction is considered to be reprocessing unless it is part of…
- 14.3Reworking
- 14.30Before a decision is taken to rework batches that do not conform to established standards or specifications, an investigation into the reas…
- 14.31Batches that have been reworked should be subjected to appropriate evaluation, testing, stability testing if warranted, and documentation t…
- 14.32Procedures should provide for comparing the impurity profile of each reworked batch against batches manufactured by the established process…
- 14.4Recovery of Materials and Solvents
- 14.40Recovery (e.g. from mother liquor or filtrates) of reactants, intermediates, or the API is considered acceptable, provided that approved pr…
- 14.41Solvents can be recovered and reused in the same processes or in different processes, provided that the recovery procedures are controlled…
- 14.42Fresh and recovered solvents and reagents can be combined if adequate testing has shown their suitability for all manufacturing processes i…
- 14.43The use of recovered solvents, mother liquors, and other recovered materials should be adequately documented.
- 14.5Returns
- 14.50Returned intermediates or APIs should be identified as such and quarantined.
- 14.51If the conditions under which returned intermediates or APIs have been stored or shipped before or during their return or the condition of…
- 14.52Records of returned intermediates or APIs should be maintained. For each return, documentation should include: - Name and address of the co…
- 15COMPLAINTS AND RECALLS
- 15.10All quality related complaints, whether received orally or in writing, should be recorded and investigated according to a written procedure.
- 15.11Complaint records should include: - Name and address of complainant; - Name (and, where appropriate, title) and phone number of person subm…
- 15.12Records of complaints should be retained in order to evaluate trends, product-related frequencies, and severity with a view to taking addit…
- 15.13There should be a written procedure that defines the circumstances under which a recall of an intermediate or API should be considered.
- 15.14The recall procedure should designate who should be involved in evaluating the information, how a recall should be initiated, who should be…
- 15.15In the event of a serious or potentially life-threatening situation, local, national, and/or international authorities should be informed a…
- 16CONTRACT MANUFACTURERS (INCLUDING LABORATORIES)
- 16.10All contract manufacturers (including laboratories) should comply with the GMP defined in this Guide. Special consideration should be given…
- 16.11Contract manufacturers (including laboratories) should be evaluated by the contract giver to ensure GMP compliance of the specific operatio…
- 16.12There should be a written and approved contract or formal agreement between the contract giver and the contract acceptor that defines in de…
- 16.13The contract should permit the contract giver to audit the contract acceptor's facilities for compliance with GMP.
- 16.14Where subcontracting is allowed, the contract acceptor should not pass to a third party any of the work entrusted to him under the contract…
- 16.15Manufacturing and laboratory records should be kept at the site where the activity occurs and be readily available.
- 16.16Changes in the process, equipment, test methods, specifications, or other contractual requirements should not be made unless the contract g…
- 17AGENTS, BROKERS, TRADERS, DISTRIBUTORS, REPACKERS, AND RELABELLERS
- 17.1Applicability
- 17.10This section applies to any party other than the original manufacturer who may trade and/or take possession, repack, relabel, manipulate, d…
- 17.11All agents, brokers, traders, distributors, repackers, and relabellers should comply with GMP as defined in this Guide.
- 17.2Traceability of Distributed APIs and Intermediates
- 17.20Agents, brokers, traders, distributors, repackers, or relabellers should maintain complete traceability of APIs and intermediates that they…
- 17.3Quality Management
- 17.30Agents, brokers, traders, distributors, repackers, or relabellers should establish, document and implement an effective system of managing…
- 17.4Repackaging, Relabelling and Holding of APIs and Intermediates
- 17.40Repackaging, relabelling and holding of APIs and intermediates should be performed under appropriate GMP controls, as stipulated in this Gu…
- 17.41Repackaging should be conducted under appropriate environmental conditions to avoid contamination and cross-contamination.
- 17.5Stability
- 17.50Stability studies to justify assigned expiration or retest dates should be conducted if the API or intermediate is repackaged in a differen…
- 17.6Transfer of Information
- 17.60Agents, brokers, distributors, repackers, or relabellers should transfer all quality or regulatory information received from an API or inte…
- 17.61The agent, broker, trader, distributor, repacker, or relabeller who supplies the API or intermediate to the customer should provide the nam…
- 17.62The agent should also provide the identity of the original API or intermediate manufacturer to regulatory authorities upon request. The ori…
- 17.63The specific guidance for Certificates of Analysis included in Section 11.4 should be met.
- 17.7Handling of Complaints and Recalls
- 17.70Agents, brokers, traders, distributors, repackers, or relabellers should maintain records of complaints and recalls, as specified in Sectio…
- 17.71If the situation warrants, the agents, brokers, traders, distributors, repackers, or relabellers should review the complaint with the origi…
- 17.72Where a complaint is referred to the original API or intermediate manufacturer, the record maintained by the agents, brokers, traders, dist…
- 17.8Handling of Returns
- 17.80Returns should be handled as specified in Section 14.52. The agents, brokers, traders, distributors, repackers, or relabellers should maint…
- 18.1General
- 18.10Section 18 is intended to address specific controls for APIs or intermediates manufactured by cell culture or fermentation using natural or…
- 18.11The term “biotechnological process” (biotech) refers to the use of cells or organisms that have been generated or modified by recombinant D…
- 18.12The term “classical fermentation” refers to processes that use microorganisms existing in nature and/or modified by conventional methods (e…
- 18.13Production of APIs or intermediates from cell culture or fermentation involves biological processes such as cultivation of cells or extract…
- 18.14Appropriate controls should be established at all stages of manufacturing to assure intermediate and/or API quality. While this Guide start…
- 18.15Appropriate equipment and environmental controls should be used to minimize the risk of contamination. The acceptance criteria for quality…
- 18.16In general, process controls should take into account: - Maintenance of the Working Cell Bank (where appropriate); - Proper inoculation and…
- 18.17Where appropriate, the removal of media components, host cell proteins, other process-related impurities, product-related impurities and co…
- 18.2Cell Bank Maintenance and Record Keeping
- 18.20Access to cell banks should be limited to authorized personnel.
- 18.21Cell banks should be maintained under storage conditions designed to maintain viability and prevent contamination.
- 18.22Records of the use of the vials from the cell banks and storage conditions should be maintained.
- 18.23Where appropriate, cell banks should be periodically monitored to determine suitability for use.
- 18.24See ICH Guideline Q5D Quality of Biotechnological Products: Derivation and Characterization of Cell Substrates Used for Production of Biote…
- 18.3Cell Culture/Fermentation
- 18.30Where aseptic addition of cell substrates, media, buffers, and gases is needed, closed or contained systems should be used where possible.…
- 18.31Where the quality of the API can be affected by microbial contamination, manipulations using open vessels should be performed in a biosafet…
- 18.32Personnel should be appropriately gowned and take special precautions handling the cultures.
- 18.33Critical operating parameters (for example temperature, pH, agitation rates, addition of gases, pressure) should be monitored to ensure con…
- 18.34Cell culture equipment should be cleaned and sterilized after use. As appropriate, fermentation equipment should be cleaned, and sanitized…
- 18.35Culture media should be sterilized before use when appropriate to protect the quality of the API.
- 18.36There should be appropriate procedures in place to detect contamination and determine the course of action to be taken. This should include…
- 18.37Records of contamination events should be maintained.
- 18.38Shared (multi-product) equipment may warrant additional testing after cleaning between product campaigns, as appropriate, to minimize the r…
- 18.4Harvesting, Isolation and Purification
- 18.40Harvesting steps, either to remove cells or cellular components or to collect cellular components after disruption, should be performed in…
- 18.41Harvest and purification procedures that remove or inactivate the producing organism, cellular debris and media components (while minimizin…
- 18.42All equipment should be properly cleaned and, as appropriate, sanitized after use. Multiple successive batching without cleaning can be use…
- 18.43If open systems are used, purification should be performed under environmental conditions appropriate for the preservation of product quali…
- 18.5Viral Removal/Inactivation steps
- 18.50See the ICH Guideline Q5A Quality of Biotechnological Products: Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines o…
- 18.51Viral removal and viral inactivation steps are critical processing steps for some processes and should be performed within their validated…
- 18.52Appropriate precautions should be taken to prevent potential viral contamination from pre-viral to post-viral removal/inactivation steps. T…
- 18.53The same equipment is not normally used for different purification steps. However, if the same equipment is to be used, the equipment shoul…
- 19.1General
- 19.10Not all the controls in the previous sections of this Guide are appropriate for the manufacture of a new API for investigational use during…
- 19.11The controls used in the manufacture of APIs for use in clinical trials should be consistent with the stage of development of the drug prod…
- 19.2Quality
- 19.20Appropriate GMP concepts should be applied in the production of APIs for use in clinical trials with a suitable mechanism of approval of ea…
- 19.21A quality unit(s) independent from production should be established for the approval or rejection of each batch of API for use in clinical…
- 19.22Some of the testing functions commonly performed by the quality unit(s) can be performed within other organizational units.
- 19.23Quality measures should include a system for testing of raw materials, packaging materials, intermediates, and APIs.
- 19.24Process and quality problems should be evaluated.
- 19.25Labelling for APIs intended for use in clinical trials should be appropriately controlled and should identify the material as being for inv…
- 19.3Equipment and Facilities
- 19.30During all phases of clinical development, including the use of small-scale facilities or laboratories to manufacture batches of APIs for u…
- 19.31Procedures for the use of facilities should ensure that materials are handled in a manner that minimizes the risk of contamination and cros…
- 19.4Control of Raw Materials
- 19.40Raw materials used in production of APIs for use in clinical trials should be evaluated by testing, or received with a supplier’s analysis…
- 19.41In some instances, the suitability of a raw material can be determined before use based on acceptability in small-scale reactions (i.e., us…
- 19.5Production
- 19.50The production of APIs for use in clinical trials should be documented in laboratory notebooks, batch records, or by other appropriate mean…
- 19.51Expected yields can be more variable and less defined than the expected yields used in commercial processes. Investigations into yield vari…
- 19.6Validation
- 19.60Process validation for the production of APIs for use in clinical trials is normally inappropriate, where a single API batch is produced or…
- 19.61Process validation should be conducted in accordance with Section 12 when batches are produced for commercial use, even when such batches a…
- 19.7Changes
- 19.70Changes are expected during development, as knowledge is gained and the production is scaled up. Every change in the production, specificat…
- 19.8Laboratory Controls
- 19.80While analytical methods performed to evaluate a batch of API for clinical trials may not yet be validated, they should be scientifically s…
- 19.81A system for retaining reserve samples of all batches should be in place. This system should ensure that a sufficient quantity of each rese…
- 19.82Expiry and retest dating as defined in Section 11.6 applies to existing APIs used in clinical trials. For new APIs, Section 11.6 does not n…
- 19.9Documentation
- 19.90A system should be in place to ensure that information gained during the development and the manufacture of APIs for use in clinical trials…
- 19.91The development and implementation of the analytical methods used to support the release of a batch of API for use in clinical trials shoul…
- 19.92A system for retaining production and control records and documents should be used. This system should ensure that records and documents ar…
- 20GLOSSARY
Cover page and contents (original)
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE
ICH HARMONISED TRIPARTITE GUIDELINE
GOOD MANUFACTURING PRACTICE GUIDE FOR ACTIVE PHARMACEUTICAL INGREDIENTS Q7
Current Step 4 version
dated 10 November 2000
This Guideline has been developed by the appropriate ICH Expert Working Group and has been subject to consultation by the regulatory parties, in accordance with the ICH Process. At Step 4 of the Process the final draft is recommended for adoption to the regulatory bodies of the European Union, Japan and USA.
Q7 Document History
New Codification First History Date Codification November 2005
Q7A Approval by the Steering Committee under Step 2 and 19 Q7 release for public consultation. July 2000
Current Step 4 version
Q7A Approval by the Steering Committee under Step 4 and 10 Q7 recommendation for adoption to the three ICH regulatory November bodies. 2000 GOOD MANUFACTURING PRACTICE GUIDE FOR ACTIVE PHARMACEUTICAL INGREDIENTS
ICH Harmonised Tripartite Guideline Having reached Step 4 of the ICH Process at the ICH Steering Committee meeting on 10 November 2000, this guideline is recommended for adoption to the three regulatory parties to ICH
TABLE OF CONTENTS
1. INTRODUCTION ........................................................................................................... 1
1.1 Objective .............................................................................................................. 1
1.2 Regulatory Applicability ...................................................................................... 1
1.3 Scope .................................................................................................................... 1
2. QUALITY MANAGEMENT ........................................................................................... 4
2.1 Principles ............................................................................................................. 4
2.2 Responsibilities of the Quality Unit(s) ............................................................... 4
2.3 Responsibility for Production Activities ............................................................. 5
2.4 Internal Audits (Self Inspection) ........................................................................ 5
2.5 Product Quality Review ....................................................................................... 6
3. PERSONNEL .................................................................................................................. 6
3.1 Personnel Qualifications ..................................................................................... 6
3.2 Personnel Hygiene ............................................................................................... 6
3.3 Consultants .......................................................................................................... 7
4. BUILDINGS AND FACILITIES ................................................................................... 7
4.1 Design and Construction ..................................................................................... 7
4.2 Utilities ................................................................................................................ 8
4.3 Water ................................................................................................................... 8
4.4 Containment ........................................................................................................ 8
4.5 Lighting ................................................................................................................ 9
4.6 Sewage and Refuse .............................................................................................. 9
4.7 Sanitation and Maintenance ............................................................................... 9
5. PROCESS EQUIPMENT ............................................................................................... 9
5.1 Design and Construction ..................................................................................... 9
5.2 Equipment Maintenance and Cleaning ............................................................ 10
5.3 Calibration ......................................................................................................... 11
5.4 Computerized Systems ...................................................................................... 11
i
6. DOCUMENTATION AND RECORDS ...................................................................... 12
6.1 Documentation System and Specifications ....................................................... 12
6.2 Equipment Cleaning and Use Record ............................................................... 12
6.3 Records of Raw Materials, Intermediates, API Labelling and Packaging Materials ............................................................................................................ 13
6.4 Master Production Instructions (Master Production and Control Records) .... 13
6.5 Batch Production Records (Batch Production and Control Records) ............... 14
6.6 Laboratory Control Records ............................................................................... 14
6.7 Batch Production Record Review ....................................................................... 15
7. MATERIALS MANAGEMENT ................................................................................... 16
7.1 General Controls ................................................................................................ 16
7.2 Receipt and Quarantine ..................................................................................... 16
7.3 Sampling and Testing of Incoming Production Materials ................................ 16
7.4 Storage ................................................................................................................ 17
7.5 Re-evaluation ..................................................................................................... 17
8. PRODUCTION AND IN-PROCESS CONTROLS ................................................... 18
8.1 Production Operations ....................................................................................... 18
8.2 Time Limits ........................................................................................................ 18
8.3 In-process Sampling and Controls ..................................................................... 18
8.4 Blending Batches of Intermediates or APIs ...................................................... 19
8.5 Contamination Control ...................................................................................... 20
9. PACKAGING AND IDENTIFICATION LABELLING OF APIS AND INTERMEDIATES ....................................................................................................... 20
9.1 General ............................................................................................................... 20
9.2 Packaging Materials .......................................................................................... 20
9.3 Label Issuance and Control ............................................................................... 20
9.4 Packaging and Labelling Operations ................................................................ 21
10. STORAGE AND DISTRIBUTION ............................................................................. 22
10.1 Warehousing Procedures ................................................................................... 22
10.2 Distribution Procedures ..................................................................................... 22
11. LABORATORY CONTROLS ...................................................................................... 22
11.1 General Controls ................................................................................................ 22
11.2 Testing of Intermediates and APIs .................................................................... 23
11.3 Validation of Analytical Procedures - see Section 12. ....................................... 24
11.4 Certificates of Analysis ...................................................................................... 24
11.5 Stability Monitoring of APIs .............................................................................. 24
11.6 Expiry and Retest Dating .................................................................................. 25
ii
11.7 Reserve/Retention Samples ............................................................................... 25
12. VALIDATION ................................................................................................................ 25
12.1 Validation Policy ................................................................................................ 25
12.2 Validation Documentation ................................................................................ 26
12.3 Qualification ...................................................................................................... 26
12.4 Approaches to Process Validation ..................................................................... 26
12.5 Process Validation Program .............................................................................. 27
12.6 Periodic Review of Validated Systems .............................................................. 27
12.7 Cleaning Validation ........................................................................................... 28
12.8 Validation of Analytical Methods ...................................................................... 28
13. CHANGE CONTROL ................................................................................................... 29
14. REJECTION AND RE-USE OF MATERIALS ......................................................... 29
14.1 Rejection............................................................................................................. 29
14.2 Reprocessing ...................................................................................................... 30
14.3 Reworking .......................................................................................................... 30
14.4 Recovery of Materials and Solvents .................................................................. 30
14.5 Returns .............................................................................................................. 31
15. COMPLAINTS AND RECALLS ................................................................................. 31
16. CONTRACT MANUFACTURERS (INCLUDING LABORATORIES) .................. 31
17. AGENTS, BROKERS, TRADERS, DISTRIBUTORS, REPACKERS, AND RELABELLERS ............................................................................................................ 32
17.1 Applicability ....................................................................................................... 32
17.2 Traceability of Distributed APIs and Intermediates ........................................ 32
17.3 Quality Management ......................................................................................... 33
17.4 Repackaging, Relabelling and Holding of APIs and Intermediates ................. 33
17.5 Stability ............................................................................................................. 33
17.6 Transfer of Information ..................................................................................... 33
17.7 Handling of Complaints and Recalls................................................................. 33
17.8 Handling of Returns .......................................................................................... 34
18. SPECIFIC GUIDANCE FOR APIS MANUFACTURED BY CELL CULTURE/FERMENTATION .................................................................................... 34
18.1 General............................................................................................................... 34
18.2 Cell Bank Maintenance and Record Keeping ................................................... 35
18.3 Cell Culture/Fermentation ................................................................................ 35
18.4 Harvesting, Isolation and Purification ............................................................. 36
18.5 Viral Removal/Inactivation steps ...................................................................... 36
iii
19. APIS FOR USE IN CLINICAL TRIALS ................................................................... 37
19.1 General ............................................................................................................... 37
19.2 Quality ................................................................................................................ 37
19.3 Equipment and Facilities ................................................................................... 37
19.4 Control of Raw Materials ................................................................................... 37
19.5 Production .......................................................................................................... 38
19.6 Validation ........................................................................................................... 38
19.7 Changes .............................................................................................................. 38
19.8 Laboratory Controls ........................................................................................... 38
19.9 Documentation ................................................................................................... 38
20. GLOSSARY ................................................................................................................... 39
iv GOOD MANUFACTURING PRACTICE GUIDE FOR ACTIVE PHARMACEUTICAL INGREDIENTS
Source: International Council for Harmonisation (ICH) · © ICH. Per the legal notice in each guideline, the document may be used, reproduced and distributed provided ICH's copyright is acknowledged; any adaptation or translation must be labelled as such and must not imply ICH endorsement. · retrieved 2026-11-15